Clinical trial · no report yet · Phase 3
PACIFIC-5
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
- NCT03706690 ↗
- Active not recruiting
- AstraZeneca
- 10 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 4 | |
| X threads | 4 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Durvalumab; Placebo
- Arms
- Durvalumab Therapy · Experimental
- Placebo Therapy · Placebo comparator
- Enrollment
- 407
- Primary outcomes
- Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)
- Sponsor
- AstraZeneca
- Start
- Nov 27, 2018
- Primary completion
- Jun 23, 2024
- Results posted
- Yes
- Registry record
- NCT03706690 · updated Aug 6, 2026
Publications
linked from the registry- Wu YL, Wu L, Bi N, Cil T, Ge H, Zhu Z, Wang CL, Zhang W, Lv D, Mingyan E, Sun J, Pan Y, Krzakowski M, Dikilitas M, Sendur MAN, Kim YC, Yang Y, Mao R, Zhang B, Wang L. PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. J Hematol Oncol. 2025 Dec 7;18(1):111. doi: 10.1186/s13045-025-01768-1. PubMed 41354932